Bertram Wiedenmann

Prof. Dr. Bertram Wiedenmann

Charité – Universitätsmedizin Berlin, 13353 Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2014 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
AAAndreas Adler
Andreas Adler
SGSebastian Geiger
Sebastian Geiger
AKAnne Keil
Anne Keil
HBHarald Bias
Harald Bias
PSPhilipp Schatz
Philipp Schatz
BWBertram Wiedenmann
Bertram Wiedenmann
Despite strong recommendations for colorectal cancer (CRC) screening, participation rates are low. Understanding factors that affect screening choices is essential to developing future screening strategies. Therefore, this study assessed patient willingness to use non-invasive stool or blood based screening tests after refusing colonoscopy.

Verified
Journal Article
Open access
PDF file
ASAnna Kathrin Stueven
Anna Kathrin Stueven
AKAntonin Kayser
Antonin Kayser
CWChristoph Wetz
Christoph Wetz
HAHolger Amthauer
Holger Amthauer
TMTobias Mueller
Tobias Mueller
HJHenning Jann
Henning Jann
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no longer available. Prognosis and survival of patients with NETs are determined by the location of the primary lesion, biochemical functional status, differentiation, initial staging, and response to treatment. Somatostatin analogue (SSA) therapy has been a mainstay of antisecretory therapy in functioning neuroendocrine tumors, which cause various clinical symptoms depending on hormonal hypersecretion. Beyond symptomatic management, recent research demonstrates that SSAs exert antiproliferative effects and inhibit tumor growth via the somatostatin receptor 2 (SSTR2). Both the PROMID (placebo-controlled, prospective, randomized study in patients with metastatic neuroendocrine midgut tumors) and the CLARINET (controlled study of lanreotide antiproliferative response in neuroendocrine tumors) trial showed a statistically significant prolongation of time to progression/progression-free survival (TTP/PFS) upon SSA treatment, compared to placebo. Moreover, the combination of SSA with peptide receptor radionuclide therapy (PRRT) in small intestinal NETs has proven efficacy in the phase 3 neuroendocrine tumours therapy (NETTER 1) trial. PRRT is currently being tested for enteropancreatic NETs versus everolimus in the COMPETE trial, and the potential of SSTR-antagonists in PRRT is now being evaluated in early phase I/II clinical trials. This review provides a synopsis on the pharmacological development of SSAs and their use as antisecretory drugs. Moreover, this review highlights the clinical evidence of SSAs in monotherapy, and in combination with other treatment modalities, as applied to the antiproliferative management of neuroendocrine tumors with special attention to recent high-quality phase III trials.

25 March 2015 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
AKAxel Kola
Axel Kola
BPBrar Piening
Brar Piening
UPUlrich-Frank Pape
Ulrich-Frank Pape
WVWilfried Veltzke-Schlieker
Wilfried Veltzke-Schlieker
MKMartin Kaase
Martin Kaase
PGPetra Gastmeier
Petra Gastmeier
Carbapenemase-producing Enterobacteriaceae (CPE) have become a major problem for healthcare systems worldwide. While the first reports from European hospitals described the introduction of CPE from endemic countries, there is now a growing number of reports describing outbreaks of CPE in European hospitals. Here we report an outbreak of Carbapenem-resistant K. pneumoniae in a German University hospital which was in part associated to duodenoscopy. Between December 6, 2012 and January 10, 2013, carbapenem-resistant K. pneumoniae (CRKP) was cultured from 12 patients staying on 4 different wards. The amplification of carbapenemase genes by multiplex PCR showed presence of the bla OXA-48 gene. Molecular typing confirmed the identity of all 12 isolates. Reviewing the medical records of CRKP cases revealed that there was a spatial relationship between 6 of the cases which were located on the same wards. The remaining 6 cases were all related to endoscopic retrograde cholangiopancreatography (ERCP) which was performed with the same duodenoscope. The outbreak ended after the endoscope was sent to the manufacturer for maintenance. Though the outbreak strain was also disseminated to patients who did not undergo ERCP and environmental sources or medical personnel also contributed to the outbreak, the gut of colonized patients is the main source for CPE. Therefore, accurate and stringent reprocessing of endoscopic instruments is extremely important, which is especially true for more complex instruments like the duodenoscope (TJF Q180V series) involved in the outbreak described here.

1 January 2008
Verified
Journal Article
Closed access
BWBertram Wiedenmann
Bertram Wiedenmann
PMPeter Malfertheiner
Peter Malfertheiner
HFHelmut Friess
Helmut Friess
PRPaul Ritch
Paul Ritch
JAJames Arseneau
James Arseneau
DHDaniel Von Hoff
Daniel Von Hoff

1 August 2019 in Clinical Nutrition
Verified
Journal Article
Closed access
SPSophie Pevny
Sophie Pevny
SMSebastian Maasberg
Sebastian Maasberg
ARAnja Rieger
Anja Rieger
MKMirjam Karber
Mirjam Karber
EBElisabeth Blüthner
Elisabeth Blüthner
UPUlrich-Frank Pape
Ulrich-Frank Pape

24 August 2020 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
Guido RindiGuido Rindi
Guido Rindi
BWBertram Wiedenmann
Bertram Wiedenmann